MARLVEL

Top 200 Drugs Study vs its rivals

Side-by-side comparison against Top 200 Drugs Study's closest competitors — identity, store metrics, ratings & sentiment, and strategic intel.

Top 200 Drugs Study
This App
Drugs.com Medication Guide
Nemesis
Medscape
Contender
Picmonic Nursing & NCLEX Study
Contender
AnkiMobile Flashcards
Peer
Quizlet: More than Flashcards
Peer
Turbo AI - Notetaker
New Kid
Core Identity
DeveloperPolemics Applications LLCDrugs.comWebMDPicmonic - The Visual Learning CommunityAnki Software, LLCQuizlet IncTurboLearn AI
CategoryEducationMedicalMedicalEducationEducationEducationEducation
PlatformiOSAndroid, iOSiOS, AndroidiOSiOSiOS, AndroidiOS, Android
Store Metrics
Rating3.0 / 54.8 / 53.6 / 54.9 / 54.1 / 54.8 / 54.8 / 5
Ratings Count213,8541,38121,0602,2331,065,43430,782
PriceUSD1.99FreeFreeFree$24.99FreeFree
Release DateJul 11, 2016Mar 1, 2013Jul 16, 2009Jun 10, 2016May 27, 2010Aug 9, 2012Jul 31, 2024
Last UpdatedApr 25, 2025Apr 15, 2026Apr 8, 2026Apr 21, 2026Sep 8, 2025Apr 14, 2026Apr 14, 2026
Sentiment & Reviews
Sentimentterriblepositive---mixed-
Score10/10065/100---48/100-
Praises-
  • Medication Management & Information
  • Pill Identification
---
  • Academic Effectiveness
  • Ease of Content Creation
-
Complaints
  • Outdated medical information in the current version prevents professional use for clinical reference
  • Monetization & Pricing
  • Technical Issues & Access
---
  • Aggressive Monetization
  • Intrusive Advertising
-
Requests-------
Strategic Intel
Strengths
  • Distraction-free interface optimizes for rapid study sessions
  • Cheat Sheet export enables viral distribution among student cohorts
  • Massive database of 24,000+ peer-reviewed medications
  • Highly-rated visual Pill Identifier tool
  • Strong consumer brand trust (25M monthly visitors)
---
  • Massive UGC library providing niche subject coverage
  • High brand equity with 1.9M+ ratings
  • Advanced AI automation for note-to-flashcard creation
-
Weaknesses
  • Content decay renders the database unreliable for clinical use
  • 3.0-star rating reflects user frustration with outdated medication lists
  • Aggressive $8.99/mo subscription pricing causing user friction
  • Technical bugs in v3.1.51 (login failures, UI duplication)
  • Manual entry for pill ID vs emerging AI camera scanning
---
  • Intrusive ads during active study sessions
  • Paywalled core features (Learn mode) causing user churn
  • Technical bugs with GIF rendering on mobile
-
Pricingpaidfreemiumfreefreemiumpaidfreemiumfreemium
MomentumMaintenanceMaintenanceIntenseIntenseMaintenanceMaintenanceIntense
Update Cadence5 versions, 4 majors/6mo, ~298d avg5 versions, ~26d avg5 versions5 versions5 versions3 versions, ~18d avg5 versions

Compare Top 200 Drugs Study head-to-head

Disclosure: Independent intel to help mobile builders succeed.

AI-powered analysis with editorial review, built from publicly available sources. Marlvel.ai is not affiliated with, endorsed by, or sponsored by Top 200 Drugs Study, its developer, the app publisher, Apple, or Google Play. All trademarks, logos, and screenshots referenced remain the property of their respective owners.

See methodologyContact support

Data licensed under CC-BY-NC 4.0